雌激素受体低表达在乳腺癌中的研究进展

Research Progress of Estrogen Receptor-Low Positive in Breast Cancer

雌激素受体(ER)状态对侵袭性乳腺癌患者的临床决策和预后预测起着重要的作用,因此激素受体检测主要用于指导乳腺癌患者的治疗选择。然而,确定ER状态和内分泌治疗资格的方法仍然存在争议。过去认为乳腺癌细胞核免疫组织化学染色ER ≥ 1%时即为ER阳性,但最新的指南将ER表达1%~10%的乳腺癌定义为“ER低表达”,这一亚组可能具有独特的分子特征,它与ER高表达的肿瘤相比,对内分泌疗法的治疗反应仍不清楚。最新的指南没有对这些患者提供详细的描述,导致治疗策略不一致。因此,我们对近期ER低表达的相关研究进行讨论分析,为ER低表达患者的临床管理提供可能的建议。

Estrogen receptor (ER) status plays an important role in clinical decision-making and prognosis prediction of patients with invasive breast cancer, so hormone receptor detection is mainly used to guide the treatment selection of patients with breast cancer. However, the method of determining ER status and eligibility for endocrine therapy remains controversial. In the past, breast tumors with ER ≥ 1% on immunohistochemical staining of nuclei were considered ER-positive, but the latest guidelines define breast cancer with ER expression of 1%~10% as “ER-low positive”, which may have a unique molecular feature, and its response to endocrine therapy remains unclear compared with tumors with high ER expression. The latest guidelines do not provide a detailed description of these patients, leading to inconsistent treatment strategies. Therefore, we discuss and analyze the relevant studies of recent ER-low positive breast cancer to provide possible suggestions for the clinical management of patients with ER-low positive.